|
gptkbp:instance_of
|
gptkb:Antihero
|
|
gptkbp:approves
|
gptkb:1993
gptkb:FDA
|
|
gptkbp:atccode
|
R06 AX13
|
|
gptkbp:available_in
|
generic form
|
|
gptkbp:available_on
|
gptkb:pharmaceuticals
|
|
gptkbp:brand
|
gptkb:Claritin
gptkb:Alavert
|
|
gptkbp:casnumber
|
79794-75-5
|
|
gptkbp:category
|
Category B
|
|
gptkbp:chemical_formula
|
C22 H23 Cl N2 O2
|
|
gptkbp:class
|
second-generation antihistamine
|
|
gptkbp:clinical_trial
|
Phase IV
Phase II
Phase III
Phase I
|
|
gptkbp:contraindication
|
hypersensitivity to loratadine
|
|
gptkbp:dosage_form
|
10 mg once daily
10 mg for children over 6 years old
5 mg for children 2 to 5 years old
|
|
gptkbp:duration
|
24 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:formulation
|
gptkb:tablet
gptkb:Sugar
disintegrating tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
loratadine
|
|
gptkbp:interacts_with
|
gptkb:beer
CYP2 D6 inhibitors
CYP3 A4 inhibitors
|
|
gptkbp:lifespan
|
8 to 14 hours
|
|
gptkbp:marketed_as
|
gptkb:Johnson_&_Johnson
gptkb:Bayer
gptkb:Schering-Plough
|
|
gptkbp:mechanism_of_action
|
H1 receptor antagonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:premiered_on
|
1 to 3 hours
|
|
gptkbp:research_areas
|
allergy treatment
hay fever treatment
hives treatment
itch treatment
seasonal allergies treatment
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
fatigue
headache
drowsiness
dry mouth
|
|
gptkbp:suitable_for
|
severe renal impairment
severe liver impairment
children under 2 years old
|
|
gptkbp:used_for
|
allergic rhinitis
chronic urticaria
|
|
gptkbp:bfsParent
|
gptkb:Claritin
gptkb:Benadryl
|
|
gptkbp:bfsLayer
|
6
|